Number of vaccines administered at Semmelweis University - 25 September 2022
539080 Total vaccines

RDI activities at Semmelweis University are carried out in the fields of life sciences and social sciences. Special emphasis is on medical, dental, pharmaceutical and health sciences, while social science research is emerging in the fields of mental health sciences. As the pace of scientific research has accelerated, Semmelweis University has laid down the foundations of a flexible and adaptable RDI system that will be able to integrate multiple new areas to harness the growth of current health industry trends and to further intensify the University’s research potential.

MAIN RESEARCH AREAS – MEDICAL SCIENCES

  • Cardiovascular research
  • Immunology research
  • Brain research
  • Imaging technology and device development

Ongoing research projects within these areas are conducted in line with the Horizon Europe 2020 Health priorities:

  • Chronic diseases
  • Healthy ageing
  • Mental health
  • Diagnostics and therapy of rare diseases
  • Effects of environmental factors on health
  • Infectious diseases and epidemiological preparedness

The intensification of research activities are expected in the following areas of clinical medicine:

  • Pharmacotherapy – research on the application of new molecules and identifying new uses for approved drugs (drug repurposing)
  • Medical devices
  • Clinical trials
  • Device development
  • preparing procedures to improve patient care
  • Medical furniture
  • Dental filling developments

MAIN RESEARCH AREAS – DENTAL SCIENCES

  • Digital dentistry
  • Dental materials science
  • Regeneration of dentoalveolar tissues
  • Molecular and cellular physiology, pathophysiology and microbiology of the oral cavity
  • Dental epidemiology

 MAIN RESEARCH AREAS – PHARMACEUTICAL SCIENCES

  • National molecule inventory
  • National phyto lab to develop natural pharmaceutical forms
  • National inventory of pharmaceutical forms
  • Artificial intelligence in pharmaceutical research
  • Innovative and nanotechnology drug development, patient centered pharmaceutical forms
  • Biotechnological drug development of biological substances

The exposure of health industry and the need for safe, flexible and innovative solutions have become more prominent due to the COVID-19 pandemic. Based on the experiences of the epidemic, it has become clear that health care and the health industry are not only undergoing digitization and digital transformation, but a data-driven paradigm shift is taking place.

Data-driven health creates a new direction for research and innovation at Semmelweis University by building on and integrating our current e-health, network research and big data research, as well as infrastructural and methodological developments. Artificial intelligence, machine learning, network research and data- and information security are our priorities in the area of data-driven health.